Pheochromocytoma and Paraganglioma

[1]  F. Beuschlein,et al.  Pheochromocytoma and paraganglioma: Clinical feature based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. , 2019, European journal of endocrinology.

[2]  J. Langenhuijsen,et al.  Pheochromocytoma and Pregnancy. , 2019, Endocrinology and metabolism clinics of North America.

[3]  W. Young,et al.  Impact of 123 I-MIBG scintigraphy on clinical decision making in pheochromocytoma and paraganglioma. , 2019, The Journal of clinical endocrinology and metabolism.

[4]  W. Young,et al.  Pheochromocytoma and Paraganglioma. , 2019, The New England journal of medicine.

[5]  W. Young,et al.  Pheochromocytoma Characteristics and Behavior Differ Depending on Method of Discovery. , 2018, The Journal of clinical endocrinology and metabolism.

[6]  F. Beuschlein,et al.  Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. , 2018, Clinical chemistry.

[7]  A. Tabarin,et al.  CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma , 2018, The Journal of clinical endocrinology and metabolism.

[8]  F. Beuschlein,et al.  Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging , 2018, Endocrine connections.

[9]  T. Links,et al.  Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review. , 2018, European journal of internal medicine.

[10]  S. Bornstein,et al.  Hypertensive crisis in pregnancy due to a metamorphosing pheochromocytoma with postdelivery Cushing's syndrome , 2018, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[11]  H. Falhammar,et al.  Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center , 2017, Endocrine connections.

[12]  T. Bednarczuk,et al.  Comparison of phenoxybenzamine and doxazosin in perioperative management of patients with pheochromocytoma. , 2017, Kardiologia polska.

[13]  B. Klink,et al.  Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas , 2017, The Journal of clinical endocrinology and metabolism.

[14]  M. Razavi,et al.  Pheochromocytoma and stress cardiomyopathy: Insight into pathogenesis , 2017, World journal of cardiology.

[15]  O. Dekkers,et al.  European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. , 2016, European journal of endocrinology.

[16]  A. Soltani,et al.  Does this patient have pheochromocytoma? A systematic review of clinical signs and symptoms , 2016, Journal of Diabetes & Metabolic Disorders.

[17]  Elise M. Blanchet,et al.  Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma , 2015, Clinical Cancer Research.

[18]  R. Hicks,et al.  Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. , 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.

[19]  M. Fassnacht,et al.  Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma. , 2015, European journal of endocrinology.

[20]  K. Pacak,et al.  Pheochromocytoma and paraganglioma. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[21]  F. Bidault,et al.  Screening in asymptomatic SDHx mutation carriers: added value of 18F-FDG PET/CT at initial diagnosis and 1-year follow-up , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  A. Gimenez-Roqueplo,et al.  Paraganglioma and phaeochromocytoma: from genetics to personalized medicine , 2015, Nature Reviews Endocrinology.

[23]  K. Pacak,et al.  Should every patient diagnosed with a phaeochromocytoma have a 123I‐MIBG scintigraphy? , 2014, Clinical endocrinology.

[24]  W. Young,et al.  Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[25]  Richard Sinnott,et al.  Biochemical diagnosis of phaeochromocytoma using plasma‐free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions , 2014, Clinical endocrinology.

[26]  F. Beuschlein,et al.  Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatographytandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma , 2013, Annals of clinical biochemistry.

[27]  J. Lenders,et al.  Mortality Associated with Phaeochromocytoma , 2013, Hormone and Metabolic Research.

[28]  A. Villringer,et al.  Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma , 2013, Annals of clinical biochemistry.

[29]  S. Bornstein,et al.  Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. , 2012, European journal of cancer.

[30]  H. Dralle,et al.  Perioperative Management of Pheochromocytoma/Paraganglioma: Is There a State of the Art? , 2012, Hormone and Metabolic Research.

[31]  K. Pacak,et al.  Current and Future Anatomical and Functional Imaging Approaches to Pheochromocytoma and Paraganglioma , 2012, Hormone and Metabolic Research.

[32]  M. Fassnacht,et al.  Long-term Postoperative Follow-up in Patients with Apparently Benign Pheochromocytoma and Paraganglioma , 2012, Hormone and Metabolic Research.

[33]  J. Lenders,et al.  Pheochromocytoma and pregnancy: a deceptive connection. , 2012, European journal of endocrinology.

[34]  L. Hofbauer,et al.  Pheochromocytoma – update on disease management , 2012, Therapeutic advances in endocrinology and metabolism.

[35]  F. Messerli,et al.  Takotsubo-like cardiomyopathy in pheochromocytoma. , 2011, International journal of cardiology.

[36]  J. Lenders,et al.  Cardiovascular manifestations of phaeochromocytoma , 2011, Journal of hypertension.

[37]  S. Bornstein,et al.  Surgery: Risks of hemodynamic instability in pheochromocytoma , 2010, Nature Reviews Endocrinology.

[38]  G. Rasp,et al.  Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. , 2009, Cancer research.

[39]  W. Manger.  The vagaries of pheochromocytomas. , 2005, American journal of hypertension.

[40]  P. Munson,et al.  Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. , 2004, Endocrine-related cancer.

[41]  C. Eng,et al.  Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. , 2004, JAMA.

[42]  J. Schipper,et al.  Germ-line mutations in nonsyndromic pheochromocytoma. , 2002, The New England journal of medicine.

[43]  F. Messerli,et al.  Clinical and Experimental Pheochromocytoma , 1997 .

[44]  K. Hirota,et al.  Pheochromocytoma with Electrocardiographic Change Mimicking Angina Pectoris, and Cyclic Change in Direct Arterial Pressure—A Case Report , 1991, Angiology.

[45]  K. Pacak,et al.  Adverse Drug Reactions in Patients with Phaeochromocytoma , 2007, Drug safety.

[46]  R. Reznek,et al.  CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas) , 2004, European Radiology.

[47]  PHÆOCHROMOCYTOMA , 1954, Journal of the Indian Medical Association.